ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Protective effect of thymoquinone against acrylamide-induced hepatotoxicity in the rat: role of MAPK and apoptosis pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Nanocarrier-Based Delivery Systems for Natural Compounds Across Research Stages.Materials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acrylamide (ACR) is widely used in industry and induces hepatotoxicity. Thymoquinone (TQ), the main constituent of the black seed (Nigella sativa L.) oil, possesses potent antioxidant and anti-apoptotic properties. The potential protective effect of TQ in ACR-induced hepatotoxicity through MAPK signaling and intrinsic/extrinsic apoptosis pathways was investigated. Animals were randomly divided into seven groups (n = 6). Control (normal saline), ACR (50 mg/kg), ACR + TQ (2.5, 5 and 10 mg/kg), ACR + vitamin E (200 mg/kg), and TQ (10 mg/kg) were administered intraperitoneally to male Wistar rats for 11 days. The content of malondialdehyde and glutathione in the liver, alanine aminotransferase, aspartate transaminase, albumin, and total serum protein were measured. Apoptosis- and mitogen-activated protein kinases (MAPK) pathway proteins in the liver were evaluated by western blotting. ACR increased AST (p < 0.001) and MDA (p < 0.01) levels and decreased GSH (p < 0.01) content in comparison to the control group. The levels of apoptosis pathway proteins (caspases 3, 8, and 9) and MAPK pathway proteins (p-p38, p-JNK, and JNK) were significantly increased in the ACR group. Co-administration of TQ (10 mg/kg) with ACR remarkably reduced AST (p < 0.01), enhanced GSH content (p < 0.001), reduced MDA level (p < 0.05), and down-regulated caspases 3, 8, and 9 (p < 0.05) and p-p38, p-JNK, and JNK proteins. ACR induces hepatotoxicity via oxidative stress and activation of MAPK and apoptosis pathways. TQ exerts a hepatoprotective effect through its antioxidant, anti-apoptotic, and MAPK-modulating properties.
Indexed as
Identifiers
41073743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.